Government builds database of every drug supply chain—citing national security.

What it does

This bill requires the federal government to maintain a list of essential medicines critical to national security and public health, assess vulnerabilities in their supply chains (especially dependence on foreign suppliers), and create a system to map and monitor pharmaceutical supply chains using data analytics. The Department of Health and Human Services coordinates the effort with the Department of Defense and other agencies, and must report regularly to Congress on supply chain risks and mitigation strategies.

Why we flagged it

The bill's core function is to map, assess, and monitor vulnerabilities in the supply chains of essential medicines, with explicit focus on national security risks and foreign dependence. It is a supply-chain transparency and resilience measure, not a price control, access expansion, or market intervention.

What the text implies

• The bill's focus on medicines sourced from or dependent on China may trigger or accelerate reshoring of pharmaceutical manufacturing, with significant capital investment and cost implications for drugmakers—potentially raising drug prices in the short term.
• The requirement to map supply chains and share data among federal agencies creates a centralized government database of pharmaceutical manufacturing locations and production volumes, which could be used for future price controls, production mandates, or export restrictions.

The full analysis lists 5 implications of this text.

Who stands to gain

domestic pharmaceutical manufacturers (potential reshoring incentives); advanced manufacturing technology providers; pharmaceutical supply chain consulting firms